Hearts & Minds Blog

Validating Our Approach: Dr. Ference to Present Results from Mendelian Randomization Studies of ACL Inhibition at the Upcoming ACC Scientific Session

Tim Mayleben

President and Chief Executive Officer

As a team of lipid management experts, we often “geek out” on the science behind LDL-cholesterol lowering therapies. That’s why we are particularly excited about this morning’s announcement regarding data from the new Mendelian randomization studies of ATP Citrate Lyase (ACL) inhibition, the target enzyme of bempedoic acid (Genetic Target Validation for ATP-Citrate Lyase Inhibition), which helps to further validate our therapeutic approach. We partnered with Dr. Brian Ference, a leading authority in Mendelian randomization techniques on these critical studies in which we sought to… more

Bringing My Life’s Work to Esperion

Tricia Mullins

Executive Director, Advocacy & Professional Relations

As February comes to a close, we reflect on the importance of recognizing American Heart Month, a time dedicated to increasing awareness and education about heart disease and prevention in the U.S.  It is also an opportunity to further focus on cardiovascular disease and talk more about it.  Many believe the burden of cardiovascular disease is under control, but the facts are just the opposite: heart disease is still the #1 cause of death here in the U.S., accounting for nearly 801,000 deaths annually, according… more

Resilient and Relentlessly Focused in 2017

Tim Mayleben

President and Chief Executive Officer

Happy New Year! We welcomed 2017 with tremendous momentum as we advanced our bempedoic acid (ETC-1002) pivotal Phase 3 LDL cholesterol lowering development program – including steadily reducing the overall program risk. The Esperion team is relentless and resilient, and we remain focused on patients and their physicians waiting on new, non-statin, complementary, cost-effective, convenient, oral, once-daily LDL-C lowering therapies. They provide us the motivation to do what we do best. First, I want to start with an update on one such patient: my wife,… more

Bempedoic Acid Mechanism of Action Paper Published in Nature Communications: Q&A with the Authors

Narendra Lalwani, PhD, MBA, FAHA

Executive Vice President, Research and Development, and Chief Operating Officer

Marianne Andreach

Senior Vice President, Strategic Marketing and Product Planning

Steve Pinkosky

Senior Scientist, Head of Translational Research

As you may have seen, Esperion scientists and collaborators recently published the definitive paper on the mechanism of action for bempedoic acid, “Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis,” in the journal Nature Communications. I sat down with authors and colleagues Narendra Lalwani and Steve Pinkosky to discuss our findings, highlights from our research and ultimately why this publication reinforces that “mechanism matters”. Marianne Andreach: Briefly describe the findings and the importance of bempedoic acid’s mechanism of action over the course… more

The History of LDL-Cholesterol with Dr. Antonio Gotto

Tim Mayleben

President and Chief Executive Officer

Antonio M. Gotto, Jr., MD, DPhil

Dean Emeritus, Weill Cornell Medicine, and Provost for Medical Affairs Emeritus, Cornell University

As you know, Esperion is focused on developing and commercializing therapies for the treatment of patients with hypercholesterolemia who are not adequately controlled by currently available lipid-modifying therapies. Like any medical innovation, the journey of bempedoic acid started long before Esperion with the earliest identification of LDL-cholesterol (LDL-C) more than a century ago. So as National Cholesterol Education Month recently came to a close, we thought this would be an appropriate time to break down the history of LDL-C lowering. Today, research and understanding of… more